Bronstein, Gewirtz & Grossman, LLC Encourages Elicio Therapeutics, Inc. (ELTX) Stockholders to Inquire abo... ACCESSWIRE
Market data is delayed by at least 15 minutes.
    Latest Story Top Stories on ELTX
    Bronstein, Gewirtz & Grossman, LLC Encourages Elicio Therapeutics, Inc. (ELTX) Stockholders to Inquire about Securities Investigation
    11:00a ET July 2 '26 ACCESSWIRE

    NEW YORK CITY, NY / ACCESS Newswire / July 2, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elicio Therapeutics, Inc. ("Elicio" or "the Company") (NASDAQ:ELTX). Investors who purchased Elicio securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELTX.

    Elicio Investigation Details

    On June 15, 2026, Elicio announced results of its Phase 2 AMPLIFY-7P study. According to the Company, "AMPLIFY-7P did not meet the pre-specified primary endpoint of disease-free survival ("DFS") in the intent-to-treat population." Following this news, Elicio's shares fell by almost 71% on the same day.

    What's Next for Elicio Investors?

    If you are aware of any facts relating to this investigation or purchased Elicio securities, you can assist this investigation by visiting the firm's site: bgandg.com/ELTX. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911

    No Cost to Elicio Investors

    We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

    Why Bronstein, Gewirtz & Grossman, LLC for Elicio Securities Investigation?

    Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

    "Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

    Follow us for updates on LinkedIn, X, Facebook, or Instagram.

    Contact Info

    Peretz Bronstein, Esq. or Nathan MillerBronstein, Gewirtz & Grossman, LLC917-590-0911 | info@bgandg.com

    Attorney advertising.

    Prior results do not guarantee similar outcomes.

    SOURCE: Bronstein, Gewirtz & Grossman, LLC

    View the original press release on ACCESS Newswire

    COMTEX_485318997/2457/2026-07-02T11:00:12

    Elicio Therapeutics Announces Pricing of $15 Million Registered Direc...
    12:25a ET July 2 '26 GlobeNewswire
    Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against...
    11:00a ET July 1 '26 ACCESSWIRE
    Elicio Therapeutics Added to Russell 2000(R) and Russell 3000(R) Inde...
    8:00a ET June 29 '26 GlobeNewswire
    Bronstein, Gewirtz & Grossman, LLC Encourages Elicio Therapeutics, In...
    11:00a ET June 26 '26 ACCESSWIRE
    Elicio Therapeutics Reports Multiple Complete Responses After ELI-002...
    7:59a ET June 17 '26 GlobeNewswire
    ELTX SHAREHOLDER INVESTIGATION: Levi & Korsinsky Investigates Elicio ...
    5:32p ET June 16 '26 ACCESSWIRE
    Elicio Therapeutics Investigation Initiated: SueWallSt Investigates t...
    4:44p ET June 16 '26 PR Newswire
    Elicio Therapeutics Investigation Initiated: SueWallSt Investigates t...
    4:44p ET June 16 '26 PR Newswire
    Levi & Korsinsky Announces Investigation of Securities Claims Against...
    12:52p ET June 16 '26 ACCESSWIRE
    Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and...
    6:59a ET June 15 '26 GlobeNewswire

    Market data provided by News provided by